Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 14, Issue 6, Pages 591-606Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543784.14.6.591
Keywords
ADAM protease; cancer; ErbB; ligand; sheddase; shedding
Categories
Ask authors/readers for more resources
A disintegrin and metalloproteases (ADAMs) are zinc-dependent transmembrane metalloproteases that shed the extracellular domains of membrane-bound growth factors, cytokines and receptors. Key functions of ADAMs have emerged in ErbB signalling pathways as being sheddases for multiple ErbB ligands. As the ErbB pathway is a validated target for anticancer drugs, the upstream activators of ErbB ligands, their sheddases, now enter the spotlight as new drug targets in the ErbB pathway. ADAMs are involved not only in tumour cell proliferation but also in angiogenesis and metastasis. Therefore, strategies targeting ADAMs might be an important complement to existing anti-ErbB approaches.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available